News and Announcements
EPIAXIS THERAPEUTICS APPOINTS DR DARREN SAUNDERS AS CHIEF SCIENCE OFFICER
- Published April 21, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
EpiAxis Therapeutics has welcomed biomedical scientist Dr Darren Saunders as its new Chief Science Officer.
The appointment follows Dr Saunders joining EpiAxis Therapeutics in October 2021 as Science and Communications Advisor.
Dr Saunders is a research scientist specialising in cancer biology, Associate Professor in Medicine at the University of Sydney and Senior Research Advisor to Elizabeth Broderick and Co. He undertook post-doctoral training at the Garvan Institute and University of British Columbia and has held fellowships from the US Dept. of Defense and Cancer Institute NSW.
Dr Saunders has made significant contributions to leadership, governance and engagement through peak professional bodies and policy development. He is a regular commentator on television and radio, resident scientist on ABC TV’s The Drum and Channel 7’s Daily Edition, and 2019 Eureka Prize winner.
“We are delighted that a scientist and skilled communicator of Dr Saunders’ calibre has chosen to join EpiAxis as its Chief Science Officer,” EpiAxis Therapeutics CEO Dr Jeremy Chrisp said. “His appointment is another significant step in the development of our Company as we continue to progress our epigenetic pipeline.”
Dr Saunders said he was excited to expand his role with EpiAxis Therapeutics during its mission to reprogram cancer and immune cells with next generation therapeutics.
“I’m excited to be joining EpiAxis at an important time for the company,” he said. “I’m really looking forward to advancing the development of new therapeutic strategies for cancer in the rapidly evolving epigenetic space.”
ABOUT EPIAXIS THERAPEUTICS:
EpiAxis is a leading drug development company that aims to make cancer a chronic disease rather than a fatal one, by using epigenetic science to create a completely different approach to cancer treatment. Our therapies work differently to existing – and often toxic – treatments by uniquely reprogramming the cancer cells back towards normal cells.
Company Updates
Stop Leaving Millions on the Table: The Investor Secret You’re Missing!
In an Australian business landscape increasingly defined by volatility and intense competition for capital, the art of robust stakeholder relations has evolved beyond a mere governance checkbox. For founders, boards, and executive teams, the ability to genuinely inform and engage investors isn’t just about meeting disclosure requirements; it’s a strategic imperative that directly impacts capital […]
Ecosystems Over Exit: Callum Laing on Disrupting Small Business M&A
At Emergence Singapore, Callum Laing of Veblen Director Program presented a bold new vision for small business M&A: “Ecosystems Over Exit.” He shared how his Unity Group takes cash-generating businesses public, focusing on growth over immediate founder exit. Discover his unique approach, how interconnected ecosystems drive massive deal flow, and a three-step framework for any business to amplify reach and capital raising.
Report on the Impact of the Proposed Unrealised Capital Gains Tax on Investment in Key Sectors
A recent survey of investors and company leaders reveals significant concerns about the proposed Unrealised Capital Gains Tax (UCGT) in Australia. Over 84% indicate it would negatively impact investment in vital renewable energy, sustainability, and life science sectors, with 82% believing it would discourage long-term holdings. The report highlights the critical role of SMSF investors in early-stage funding and urges policymakers to reconsider the tax’s potential to stifle innovation and economic growth.
Backed By Leading Investment Groups and Family Offices
